Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $2.71 Million Stock Position in BioMarin Pharmaceutical Inc. $BMRN

Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 8.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,273 shares of the biotechnology company’s stock after acquiring an additional 3,716 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in BioMarin Pharmaceutical were worth $2,709,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Nuveen LLC acquired a new stake in BioMarin Pharmaceutical in the 1st quarter worth $184,475,000. AQR Capital Management LLC raised its position in shares of BioMarin Pharmaceutical by 127.9% during the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock valued at $203,987,000 after buying an additional 1,642,206 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of BioMarin Pharmaceutical by 212.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after buying an additional 1,083,512 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new stake in BioMarin Pharmaceutical during the first quarter worth about $59,125,000. Finally, Robeco Institutional Asset Management B.V. grew its position in BioMarin Pharmaceutical by 559.8% during the second quarter. Robeco Institutional Asset Management B.V. now owns 641,718 shares of the biotechnology company’s stock worth $35,275,000 after buying an additional 544,457 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have commented on BMRN. Truist Financial cut their price target on BioMarin Pharmaceutical from $90.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, October 28th. Morgan Stanley cut their target price on BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a research note on Tuesday, October 28th. HC Wainwright reduced their target price on BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating for the company in a research report on Monday, October 27th. Wells Fargo & Company lowered their price target on shares of BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, October 28th. Finally, Barclays dropped their price objective on shares of BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating for the company in a research note on Tuesday, October 28th. Sixteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ:BMRN opened at $52.56 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.60. The business’s fifty day moving average price is $53.71 and its two-hundred day moving average price is $56.33. BioMarin Pharmaceutical Inc. has a fifty-two week low of $50.76 and a fifty-two week high of $73.51. The stock has a market capitalization of $10.10 billion, a price-to-earnings ratio of 19.76, a price-to-earnings-growth ratio of 0.68 and a beta of 0.33.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Monday, October 27th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.20). The firm had revenue of $776.13 million during the quarter, compared to analyst estimates of $782.42 million. BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.91 EPS. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. As a group, analysts predict that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.